DK3307262T3 - Forbindelser til anvendelse ved behandling af neuromuskulære lidelser - Google Patents

Forbindelser til anvendelse ved behandling af neuromuskulære lidelser Download PDF

Info

Publication number
DK3307262T3
DK3307262T3 DK16738352.0T DK16738352T DK3307262T3 DK 3307262 T3 DK3307262 T3 DK 3307262T3 DK 16738352 T DK16738352 T DK 16738352T DK 3307262 T3 DK3307262 T3 DK 3307262T3
Authority
DK
Denmark
Prior art keywords
compounds
treatment
neuromuscular disorders
neuromuscular
disorders
Prior art date
Application number
DK16738352.0T
Other languages
English (en)
Inventor
Pedersen Thomas Holm
Martin Broch-Lips
Olesen Claus Elsborg
Marc Labelle
Nielsen Ole Bækgaard
Original Assignee
Nmd Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nmd Pharma As filed Critical Nmd Pharma As
Application granted granted Critical
Publication of DK3307262T3 publication Critical patent/DK3307262T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/48—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/135—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK16738352.0T 2015-06-15 2016-06-15 Forbindelser til anvendelse ved behandling af neuromuskulære lidelser DK3307262T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175590P 2015-06-15 2015-06-15
PCT/DK2016/050186 WO2016202341A1 (en) 2015-06-15 2016-06-15 Compounds for use in treating neuromuscular disorders

Publications (1)

Publication Number Publication Date
DK3307262T3 true DK3307262T3 (da) 2021-08-09

Family

ID=56409450

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16738352.0T DK3307262T3 (da) 2015-06-15 2016-06-15 Forbindelser til anvendelse ved behandling af neuromuskulære lidelser

Country Status (15)

Country Link
US (1) US10934244B2 (da)
EP (1) EP3307262B1 (da)
JP (1) JP6798075B2 (da)
KR (1) KR102722949B1 (da)
CN (1) CN107820425B (da)
AU (1) AU2016279486B2 (da)
BR (1) BR112017026739A2 (da)
CA (1) CA2986611C (da)
DK (1) DK3307262T3 (da)
ES (1) ES2879826T3 (da)
IL (1) IL256166B (da)
MX (1) MX389242B (da)
RU (1) RU2745065C2 (da)
WO (1) WO2016202341A1 (da)
ZA (1) ZA201707852B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
HRP20170936T1 (hr) 2009-02-16 2017-09-22 Nogra Pharma Limited Alkilamido spojevi i njihova uporaba
WO2013117744A2 (en) 2012-02-09 2013-08-15 Nogra Pharma Limited Methods of treating fibrosis
DK3307262T3 (da) 2015-06-15 2021-08-09 Nmd Pharma As Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
TWI780281B (zh) 2017-12-14 2022-10-11 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
US20190183812A1 (en) * 2017-12-14 2019-06-20 Nmd Pharma A/S Compounds For The Treatment Of Neuromuscular Disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
TWI794369B (zh) 2017-12-14 2023-03-01 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2019241663A1 (en) 2018-06-15 2019-12-19 Afecta Pharmaceuticals, Inc. Ccl5 inhibitors
CN111035813B (zh) * 2018-10-15 2022-02-18 复旦大学附属中山医院 一种液体创可贴式冠脉带膜支架及其制作方法
AU2020217884B2 (en) 2019-02-08 2025-02-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
KR102900834B1 (ko) 2019-06-19 2025-12-16 엔엠디 파마 에이/에스 Clc-1 클로라이드 채널 억제제의 제조 방법
US12415771B2 (en) 2019-06-19 2025-09-16 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
EP3753560A1 (en) * 2019-06-19 2020-12-23 NMD Pharma A/S Compounds for the treatment of neuromuscular disorders
US12168643B2 (en) 2019-06-19 2024-12-17 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2024261020A1 (en) 2023-06-20 2024-12-26 Nmd Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases
WO2025196206A1 (en) * 2024-03-20 2025-09-25 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2025196186A1 (en) * 2024-03-20 2025-09-25 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA676827A (en) 1963-12-24 The Sherwin-Williams Company Of Canada Limited Herbicidal compositions
GB573476A (en) 1943-04-21 1945-11-22 Reginald Thomas Foster Improvements in or relating to the manufacture of chlorinated phenoxy compounds
GB822199A (en) 1956-09-18 1959-10-21 Boots Pure Drug Co Ltd Process for the preparation of alpha-phenoxyalkanoic acids
FR1451171A (fr) 1961-04-21 1966-01-07 Jacques Logeais Soc D Expl Des Dérivés éthérifiés et estérifiés de l'o-hydroxy-phényl-2 oxadiazole-1, 3, 4 et leur procédé de préparation
US3544560A (en) 1968-07-19 1970-12-01 Carter Wallace Penicillin compounds
FR2306697A1 (fr) 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
JPS5219632U (da) 1975-07-30 1977-02-12
IT1065062B (it) 1975-08-08 1985-02-25 Hoffmann La Roche Esteri di acidi alfa arilossicar bossilici sostituiti
US4283472A (en) 1980-02-26 1981-08-11 Eastman Kodak Company Silver halide elements containing blocked pyrazolone magenta dye-forming couplers
US4337267A (en) 1980-08-25 1982-06-29 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, their use and medicaments containing them
DE3460315D1 (en) 1983-02-19 1986-08-28 Beecham Group Plc Benzofuran and benzothiophene-carboxylic-acid derivatives
FR2551063A1 (fr) 1983-08-22 1985-03-01 Inst Nat Sante Rech Med Nouveaux dimethyl-2,5 pyrroles, leur procede de preparation et leur application en therapeutique
FI870445A0 (fi) * 1985-06-14 1987-02-02 Pfizer Mellanprodukt vid framstaellning av asymmetrisk hydantoin.
NO170884C (no) 1986-08-18 1992-12-23 Hoffmann La Roche Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrimidinderivater
US4803301A (en) * 1988-04-13 1989-02-07 Kirin Beer Kabushiki Kaisha Process for producing optically active 2-phenoxypropionic acid
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5025031A (en) 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
EP0593491B1 (en) * 1991-04-25 1996-10-23 DEGHENGHI, Romano Luteinizing hormone releasing hormone antagonist peptides
TW259690B (da) 1992-08-01 1995-10-11 Hoechst Ag
DE4314962A1 (de) 1993-05-06 1994-11-10 Bayer Ag Substituierte Piperazine
DE69408373T2 (de) 1993-06-01 1998-07-16 Ono Pharmaceutical Co Pentansäurederivate
BR9808042A (pt) * 1997-03-25 2000-03-08 Astra Pharma Prod Composto, composição farmacêutica, e, processo para preparação de compostos.
EP1265857A1 (en) 2000-03-13 2002-12-18 Eli Lilly And Company Sulfonamide derivatives
WO2001091738A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating amyotrophic lateral sclerosis
WO2002057222A2 (en) * 2001-01-17 2002-07-25 Guilford Pharmaceuticals Inc. Thiol-based naaladase inhibitors
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
CA2446879A1 (en) * 2001-05-11 2002-11-21 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
AU2002325614A1 (en) * 2001-08-16 2003-03-03 Pharmacon-Forschung Und Beratung Gmbh Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances
EP1596860A4 (en) 2003-02-14 2009-05-27 Smithkline Beecham Corp NEW CONNECTIONS
AU2004232682B2 (en) 2003-03-28 2006-12-07 Eli Lilly And Company Isoquinoline-5-sulfonic acid amides as inhibitors of Akt (protein kinase B)
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7034051B2 (en) 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
US20080200499A1 (en) 2004-07-20 2008-08-21 Reiner Fischer Selective Insecticides and/or Acaricides Based on Substituted Cyclic Dicarbonyl Compounds and Safeners
DE102004035131A1 (de) * 2004-07-20 2006-02-16 Bayer Cropscience Ag Selektive Insektizide und/oder Akarizide auf Basis von substituierten, cyclischen Dicarbonylverbindungen und Safenern
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
WO2007030886A1 (en) 2005-09-16 2007-03-22 Nufarm Australia Limited Herbicide mixtures and process for preparation thereof
CA2625572A1 (en) * 2005-11-17 2007-05-24 Pfizer Limited Amino acid derivatives
WO2007062678A1 (en) * 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
ATE484506T1 (de) * 2006-12-11 2010-10-15 Merck Sharp & Dohme Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
FR2917424B1 (fr) 2007-06-12 2012-10-19 Inst Francais Du Petrole Production de charges de vapocraquage a haut rendement en ethylene, propylene et polymeres resultants par hydrotraitement d'huile vegetales
US8742183B2 (en) 2007-12-21 2014-06-03 Uop Llc Production of aviation fuel from biorenewable feedstocks
US8324438B2 (en) 2008-04-06 2012-12-04 Uop Llc Production of blended gasoline and blended aviation fuel from renewable feedstocks
CN101402537B (zh) * 2008-11-12 2011-04-27 中国科学院广州生物医药与健康研究院 2-吡啶-β酮类化合物的应用
ES2436550T3 (es) 2009-04-20 2014-01-02 F. Hoffmann-La Roche Ag Nuevos derivados de prolina como inhibidores de catepsina
US8394900B2 (en) 2010-03-18 2013-03-12 Syntroleum Corporation Profitable method for carbon capture and storage
WO2011133920A1 (en) * 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP5800898B2 (ja) 2010-07-05 2015-10-28 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
US9493451B2 (en) 2011-05-16 2016-11-15 Bionomics Limited Amine derivatives as potassium channel blockers
AU2012281019B2 (en) 2011-07-13 2016-05-12 Microbiotix, Inc. Inhibitors of bacterial type III secretion system
FR2978643B1 (fr) 2011-08-02 2014-01-31 Ard Sa Composition herbicide a efficacite amelioree, methode de preparation et utilisation
EP2758385B1 (en) 2011-09-19 2018-03-28 MSN Laboratories Limited Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof
TW201343629A (zh) 2012-01-31 2013-11-01 Lilly Co Eli 可作為ｍｏｇａｔ－２抑制劑之新穎芐磺醯胺衍生物
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN102771479B (zh) 2012-08-31 2014-04-16 广西田园生化股份有限公司 一种含环嗪酮与苯氧羧酸类的除草组合物
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US20160221965A1 (en) 2013-09-16 2016-08-04 Bayer Pharma Aktiengesellschaft Disubstituted trifluoromethyl pyrimidinones and their use
AR097631A1 (es) 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
CN105440020B (zh) 2013-12-10 2018-12-18 常州大学 具有抗肿瘤活性的1,2,3-三唑类化合物及其制备方法
JP2015231988A (ja) 2014-05-12 2015-12-24 大正製薬株式会社 ２−ピリドン化合物
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
DK3307262T3 (da) 2015-06-15 2021-08-09 Nmd Pharma As Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
KR101829102B1 (ko) 2015-09-25 2018-02-14 경희대학교 산학협력단 크로마논 2-카르복실산 유도체, 크로만 2-카르복실산 유도체 및 이의 제조방법
MA44083A (fr) 2015-12-15 2021-06-02 Merck Sharp & Dohme Composés de biarylmonobactame pour le traitement d'infections bactériennes
RU2019123404A (ru) 2016-12-27 2021-02-01 Дайити Санкио Компани, Лимитед Производное пиримидина
TWI780281B (zh) 2017-12-14 2022-10-11 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物

Also Published As

Publication number Publication date
US20180099920A1 (en) 2018-04-12
ES2879826T3 (es) 2021-11-23
HK1252978A1 (zh) 2019-06-06
CN107820425A (zh) 2018-03-20
MX2017016424A (es) 2019-08-01
AU2016279486A1 (en) 2018-01-25
BR112017026739A2 (pt) 2018-08-28
JP2018517760A (ja) 2018-07-05
CN107820425B (zh) 2021-08-31
CA2986611C (en) 2023-10-03
RU2017143609A3 (da) 2019-10-30
EP3307262A1 (en) 2018-04-18
IL256166B (en) 2020-10-29
KR102722949B1 (ko) 2024-10-28
CA2986611A1 (en) 2016-12-22
MX389242B (es) 2025-03-20
AU2016279486B2 (en) 2021-04-01
US10934244B2 (en) 2021-03-02
ZA201707852B (en) 2021-08-25
RU2017143609A (ru) 2019-07-15
RU2745065C2 (ru) 2021-03-18
KR20180012858A (ko) 2018-02-06
IL256166A (en) 2018-02-28
EP3307262B1 (en) 2021-05-19
JP6798075B2 (ja) 2020-12-09
WO2016202341A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL257252A (en) Methods of treating fgf21-associated disorders
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3524255T3 (da) Sammensætning til behandling af acne
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose